A Cal­i­for­nia biotech steps in­to the vi­ral vec­tor space with new site build of $75M

As cell and gene ther­a­py gets hot­ter, a Cal­i­for­nia CD­MO has made a play to open an en­tire­ly new arm of its op­er­a­tions to fill a void in the mar­ket.

Avid Bioser­vices will move in­to the cell and gene ther­a­py mar­ket, with the con­struc­tion of a 53,000 square-foot vi­ral vec­tor cGMP man­u­fac­tur­ing site down the road from its Tustin, CA head­quar­ters.

The site will be com­plet­ed with­in 18 months, with CEO Nicholas Green say­ing that Jan­u­ary 2023 is an an­tic­i­pat­ed open­ing date. If the project stays on track, its an­a­lyt­i­cal and process de­vel­op­ment labs could be ready for par­tial use in the next six to eight months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER